MYC and breast cancer: Consequently, the inhibitory effect on cell growth induced by CDK2i and CDK4/6i combined with ET could be, at least in part, a result of the impaired oncogenic activity of c-Myc that further inhibits S6 in AI-resistant and combined CDK4/6i and fulvestrant-resistant ER+ BC cells.